^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Adjuvant Treatment...Useful in Certain Circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating mutation…vemurafenib…
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.